Shire puts Fabry drug plant in Genzyme's back yard; CryoPort brings green to frozen shipping;

> Irish drugmaker Shire says the European Medicines Agency has approved a new manufacturing site for Fabry disease treatment Replagal in Lexington, MA, a mere 10 miles from the Genzyme plant now under consent decree remediation, site of Fabrazyme production. Item

> Cold chain provider CryoPort says it's targeting the frozen shipping market with products that both benefit life sciences companies and represent "green" technology solutions. Article

> Fakes fighter and brand protection specialist Sproxil, known for pioneering efforts in cell-phone-based drug authentication in Nigeria, has received $1.8 million from Acumen to kick start the technology in India and East Africa. Item

> A seasoned crop of pharma execs have launched BioEndpoint Consulting, targeting small and mid-sized drugmakers navigating the intricacies of development and commercialization. Release

> Process analytical instrument maker Applied Instrument Technologies has opened its new corporate HQ and manufacturing facility in Upland, CA. Release

> Pfizer has teamed with the U.S. Department of Homeland Security and Eaton in a National Press Club panel discussion on the growing threat of counterfeit products. Announcement

> Novato, CA-based biotech BioMarin Pharmaceutical says it will pay $48.5 million to acquire a 10-acre manufacturing plant in Ireland from Pfizer. Story

> A high-end May & Baker drug plant now graces Ota in Ogun State, Nigeria; 10,769 square meters for capacity of 4 billion tablets, 30 million bottles of liquid preparation annually; man/material movement in non-crossing patterns for separate personnel and material flows; and WHO, FDA and other globally recognized regulatory compliance. Story

> A Scottish chemical factory on the verge of closing has been taken over by Bakhu Pharma for manufacturing anti-cholesterol and HIV drugs. Story

> The Serbian government, which will provide a $100 million loan, said last week that drugmaker Galenika can resume production, avoiding a national drug shortage. Article

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)